{"meta":{"id":"https:\/\/api.iclient.ifeng.com\/ipadtestdoc?aid=ucms_7xW9dRoqNMK","type":"doc","o":"1","documentId":"ucms_7xW9dRoqNMK"},"body":{"newStatus":"1","documentId":"ucms_7xW9dRoqNMK","staticId":"ucms_7xW9dRoqNMK","title":"兴齐眼药:环孢素滴眼液(Ⅱ)获药品注册批件","shareTitle":"兴齐眼药:环孢素滴眼液(Ⅱ)获药品注册批件","thumbnail_doc":"","thumbnail":"","source":"证券时报","author":"","editorcode":"weMedia","editTime":"2020-06-22 20:41:29","updateTime":"2020\/06\/22 20:41:29","wapurl":"http:\/\/\/\/finance.ifeng.com\/c\/7xW9dRoqNMK","introduction":"","wwwurl":"http:\/\/\/\/finance.ifeng.com\/c\/7xW9dRoqNMK","commentsUrl":"ucms_7xW9dRoqNMK","commentCount":0,"text":"
证券时报e公司讯,兴齐眼药(300573)6月22日晚间公告,公司收到国家药监局核准签发的环孢素滴眼液(Ⅱ)《药品注册批件》。公司获批的环孢素滴眼液(Ⅱ)可促进干眼症患者的泪液分泌,适用于与角结膜干燥症相关的眼部炎症所导致的泪液生成减少的患者。目前公司已着手进行环孢素滴眼液(Ⅱ)上市准备工作。环孢素滴眼液(Ⅱ)是中国首个获批上市的用于干眼症的环孢素眼用制剂。<\/p>","img":[],"summary":"证券时报e公司讯,兴齐眼药(300573)6月22日晚间公告,公司收到国家药监局核准签发的环孢素滴眼液(Ⅱ)《药品注册批件》。公司获批的环孢素滴眼液(Ⅱ)可促进","sharesummary":"证券时报e公司讯,兴齐眼药(300573)6月22日晚间公告,公司收到国家药监局核准签发的环孢素滴眼液(Ⅱ)《药品注册批件》。公司获批的环孢素滴眼液(Ⅱ)可促进","commentType":"0","wemediaEAccountId":"706","showclient":"0","shareurl":"https:\/\/ishare.ifeng.com\/c\/s\/v002S98zfAJuszF5dvsTOJbjP--nP20I23VvlAebVl-_p8his__","praise":"0","like_num":"0"}}